Consequences of Chronic Inflammation in Peritoneal Dialysis

Seminars in Nephrology

Volumn 31, Issue 2, 2011, Pages 159-171

  Wang, Angela Yee Moon ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiovascular; Inflammation; Mortality; Peritoneal dialysis

Indexed keywords

ANOREXIA; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CACHEXIA; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERMETABOLISM; INSULIN RESISTANCE; KIDNEY FAILURE; LONG TERM CARE; MALNUTRITION; MORTALITY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

C-REACTIVE PROTEIN; CACHEXIA; CALCINOSIS; CARDIOMEGALY; CHRONIC DISEASE; HEART FAILURE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; OSTEOPROTEGERIN; PERITONEAL DIALYSIS; PREVALENCE;

EID: 79952778908     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.01.005     Document Type: Article

References (131)

1. Collins A.J., Foley R.N., Herzog C., et al. United States Renal Data System 2008 annual data report. Am J Kidney Dis 2009, 53:S1-S374.
2. Wang A.Y. Prognostic value of C-reactive protein for heart disease in dialysis patients. Curr Opin Investig Drugs 2005, 6:879-886.
3. Haubitz M., Brunkhorst R., Wrenger E., Froese P., Schulze M., Koch K.M. Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Perit Dial Int 1996, 16:158-162.
4. Welten A.G., Schalkwijk C.G., ter Wee P.M., Meijer S., van den Born J., Beelen R.J. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 2003, 23:213-221.
5. Stenvinkel P., Heimburger O., Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002, 39:274-282.
6. Niessner A., Kaun C., Zorn G., et al. Polymorphic membrane protein (PMP) 20 and PMP 21 of Chlamydia pneumoniae induce proinflammatory mediators in human endothelial cells in vitro by activation of the nuclear factor-kappaB pathway. J Infect Dis 2003, 188:108-113.
7. Nadeem M., Stephen L., Schubert C., Davids M.R. Association between periodontitis and systemic inflammation in patients with end-stage renal disease. SADJ 2009, 64:470-473.
8. Liu Y., Berthier-Schaad Y., Fallin M.D., et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 2006, 17:863-870.
9. Muntinghe F.L., Verduijn M., Zuurman M.W., et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 2009, 20:1641-1649.
10. Wang A.Y., Woo J., Lam C.W., et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients?. J Am Soc Nephrol 2003, 14:1871-1879.
11. Wang A.Y., Lam C.W., Chan I.H., Wang M., Lui S.F., Sanderson J.E. Long-term mortality and cardiovascular risk stratification of peritoneal dialysis patients using a combination of inflammation and calcification markers. Nephrol Dial Transplant 2009, 24:3826-3833.
12. Wang A.Y., Lam C.W., Wang M., et al. Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am J Kidney Dis 2005, 45:715-729.
13. Wang A.Y., Lam C.W., Chan I.H., Wang M., Lui S.F., Sanderson J.E. Prognostic value of plasma myeloperoxidase in ESRD patients. Am J Kidney Dis 2010, 56:937-946.
14. Chung S.H., Heimburger O., Stenvinkel P., Bergstrom J., Lindholm B. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001, 16:2240-2245.
15. Pecoits-Filho R., Heimburger O., Barany P., et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003, 41:1212-1218.
16. Descamps-Latscha B., Herbelin A., Nguyen A.T., et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 1995, 154:882-892.
17. Poole S., Bird T.A., Selkirk S., et al. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 1990, 2:416-422.
18. Bemelmans M.H., Gouma D.J., Buurman W.A. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993, 150:2007-2017.
19. Glorieux G., Cohen G., Jankowski J., Vanholder R. Platelet/leukocyte activation, inflammation, and uremia. Semin Dial 2009, 22:423-427.
20. Herbelin A., Urena P., Nguyen A.T., Zingraff J., Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991, 39:954-960.
21. Axelsson J., Rashid Qureshi A., Suliman M.E., et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004, 80:1222-1229.
22. Martins C., Mazza do Nascimento M., Pecoits-Filho R., et al. Insulin resistance is associated with circulating fibrinogen levels in nondiabetic patients receiving peritoneal dialysis. J Ren Nutr 2007, 17:132-137.
23. Mohamed-Ali V., Goodrick S., Rawesh A., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200.
24. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
25. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
26. Bergstrom J. Inflammation, malnutrition, cardiovascular disease and mortality in end-stage renal disease. Pol Arch Med Wewn 2000, 104:641-643.
27. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999, 55:648-658.
28. Wanner C., Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002, 17(Suppl 8):29-32. discussion 9-40.
29. Herzig K.A., Purdie D.M., Chang W., et al. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients?. J Am Soc Nephrol 2001, 12:814-821.
30. Noh H., Lee S.W., Kang S.W., et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998, 18:387-394.
31. Iseki K., Tozawa M., Yoshi S., Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999, 14:1956-1960.
32. Ducloux D., Bresson-Vautrin C., Kribs M., Abdelfatah A., Chalopin J.M. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002, 62:1417-1422.
33. Parekh R.S., Plantinga L.C., Kao W.H., et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int 2008, 74:1335-1342.
34. Wang A.Y., Lam C.W., Chan I.H., Wang M., Lui S.F., Sanderson J.E. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 2010, 56:210-216.
35. Barreto D.V., Barreto F.C., Liabeuf S., et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2010, 77:550-556.
36. Bologa R.M., Levine D.M., Parker T.S., et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998, 32:107-114.
37. Rao M., Guo D., Perianayagam M.C., et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005, 45:324-333.
38. Pecoits-Filho R., Barany P., Lindholm B., Heimburger O., Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002, 17:1684-1688.
39. Tripepi G., Mallamaci F., Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005, 16(Suppl 1):S83-S88.
40. Stenvinkel P., Heimburger O., Wang T., Lindholm B., Bergstrom J., Elinder C.G. High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis 1999, 34:1083-1088.
41. Suliman M.E., Qureshi A.R., Carrero J.J., et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. QJM 2008, 101:397-405.
42. Wang A.Y., Woo J., Lam C.W., et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005, 20:1676-1685.
43. Raj D.S., Shah V.O., Rambod M., Kovesdy C.P., Kalantar-Zadeh K. Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis. Am J Kidney Dis 2009, 54:1062-1071.
44. Korevaar J.C., van Manen J.G., Dekker F.W., de Waart D.R., Boeschoten E.W., Krediet R.T. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 2004, 15:2916-2922.
45. Nascimento M.M., Pecoits-Filho R., Qureshi A.R., et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant 2004, 19:2803-2809.
46. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
47. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
48. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439-1441.
49. Wang C.H., Li S.H., Weisel R.D., et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003, 107:1783-1790.
50. Han K.H., Hong K.H., Park J.H., et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004, 109:2566-2571.
51. Wolbink G.J., Brouwer M.C., Buysmann S., ten Berge I.J., Hack C.E. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996, 157:473-479.
52. Griselli M., Herbert J., Hutchinson W.L., et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999, 190:1733-1740.
53. Bhakdi S., Torzewski M., Klouche M., Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999, 19:2348-2354.
54. Zwaka T.P., Hombach V., Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001, 103:1194-1197.
55. Verma S., Kuliszewski M.A., Li S.H., et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004, 109:2058-2067.
56. Torzewski J., Torzewski M., Bowyer D.E., et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998, 18:1386-1392.
57. Kim S.B., Min W.K., Lee S.K., Park J.S., Hong C.D., Yang W.S. Persistent elevation of C-reactive protein and ischemic heart disease in patients with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2002, 39:342-346.
58. Zoccali C., Benedetto F.A., Mallamaci F., et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 2000, 18:1207-1213.
59. Wang A.Y., Ho S.S., Liu E.K., et al. Differential associations of traditional and non-traditional risk factors with carotid intima-media thickening and plaque in peritoneal dialysis patients. Am J Nephrol 2007, 27:458-465.
60. Huber S.A., Sakkinen P., Conze D., Hardin N., Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999, 19:2364-2367.
61. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
62. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Lepage S., Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000, 101:2149-2153.
63. Addabbo F., Mallamaci F., Leonardis D., et al. Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrol Dial Transplant 2007, 22:3521-3526.
64. Wang A.Y. Vascular and other tissue calcification in peritoneal dialysis patients. Perit Dial Int 2009, 29(Suppl 2):S9-S14.
65. Blacher J., Guerin A.P., Pannier B., Marchais S.J., London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001, 38:938-942.
66. Wang A.Y., Wang M., Woo J., et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003, 14:159-168.
67. Giachelli C.M. Vascular calcification mechanisms. J Am Soc Nephrol 2004, 15:2959-2964.
68. Raggi P., Boulay A., Chasan-Taber S., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J Am Coll Cardiol 2002, 39:695-701.
69. Wang A.Y., Ho S.S., Wang M., et al. Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease. Arch Intern Med 2005, 165:327-332.
70. Wang A.Y., Woo J., Wang M., et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2001, 12:1927-1936.
71. Tintut Y., Patel J., Parhami F., Demer L.L. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000, 102:2636-2642.
72. Qiao J.H., Xie P.Z., Fishbein M.C., et al. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb 1994, 14:1480-1497.
73. Jung H.H., Kim S.W., Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 2006, 21:1915-1920.
74. Yamada K., Fujimoto S., Nishiura R., et al. Risk factors of the progression of abdominal aortic calcification in patients on chronic haemodialysis. Nephrol Dial Transplant 2007, 22:2032-2037.
75. Gross M.L., Meyer H.P., Ziebart H., et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol 2007, 2:121-134.
76. Wang A.Y., Lam C.W., Wang M., et al. Increased circulating inflammatory proteins predict a worse prognosis with valvular calcification in end-stage renal disease: a prospective cohort study. Am J Nephrol 2008, 28:647-653.
77. Lebreton J.P., Joisel F., Raoult J.P., Lannuzel B., Rogez J.P., Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979, 64:1118-1129.
78. Wang H., Zhang M., Soda K., Sama A., Tracey K.J. Fetuin protects the fetus from TNF. Lancet 1997, 350:861-862.
79. Schafer C., Heiss A., Schwarz A., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003, 112:357-366.
80. Schoppet M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002, 22:549-553.
81. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
82. Jono S., Ikari Y., Shioi A., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
83. Shroff R.C., Shah V., Hiorns M.P., et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008, 23:3263-3271.
84. Nitta K., Akiba T., Uchida K., et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003, 42:303-309.
85. Morena M., Terrier N., Jaussent I., et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006, 17:262-270.
86. Foley R.N., Parfrey P.S., Harnett J.D., et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995, 47:186-192.
87. Aoki J., Ikari Y., Nakajima H., et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 2005, 67:333-340.
88. Park C.W., Shin Y.S., Kim C.M., et al. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis 2002, 40:1230-1239.
89. Wang A.Y., Lam C.W., Wang M., Chan I.H., Lui S.F., Sanderson J.E. Is valvular calcification a part of the missing link between residual kidney function and cardiac hypertrophy in peritoneal dialysis patients?. Clin J Am Soc Nephrol 2009, 4:1629-1636.
90. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236-241.
91. Tsutamoto T., Hisanaga T., Wada A., et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998, 31:391-398.
92. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704-711.
93. Habib F.M., Springall D.R., Davies G.J., Oakley C.M., Yacoub M.H., Polak J.M. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996, 347:1151-1155.
94. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000, 102:3060-3067.
95. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103:2055-2059.
96. Bozkurt B., Kribbs S.B., Clubb F.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97:1382-1391.
97. Kubota T., McTiernan C.F., Frye C.S., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997, 81:627-635.
98. Sivasubramanian N., Coker M.L., Kurrelmeyer K.M., et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001, 104:826-831.
99. Janssen S.P., Gayan-Ramirez G., Van den Bergh A., et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005, 111:996-1005.
100. Balligand J.L., Ungureanu D., Kelly R.A., et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993, 91:2314-2319.
101. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999, 353:1838-1842.
102. Baumgarten G., Knuefermann P., Kalra D., et al. Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation 2002, 105:2192-2197.
103. Saito Y., Berk B.C. Angiotensin II-mediated signal transduction pathways. Curr Hypertens Rep 2002, 4:167-171.
104. Sciarretta S., Paneni F., Palano F., et al. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 2009, 116:467-477.
105. Kan H., Finkel M.S. Interactions between cytokines and neurohormonal systems in the failing heart. Heart Fail Rev 2001, 6:119-127.
106. Murray D.R., Prabhu S.D., Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000, 101:2338-2341.
107. Wang A.Y., Wang M., Woo J., et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004, 15:2186-2194.
108. Stenvinkel P., Heimburger O., Paultre F., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999, 55:1899-1911.
109. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996, 7:198-207. Canada-USA (CANUSA) Peritoneal Dialysis Study Group.
110. Fouque D., Kalantar-Zadeh K., Kopple J., et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008, 73:391-398.
111. Wang A.Y., Sanderson J., Sea M.M., et al. Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis. Am J Clin Nutr 2003, 77:834-841.
112. Wang A.Y., Sea M.M., Tang N., et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol 2004, 15:3134-3143.
113. Kalantar-Zadeh K., Block G., McAllister C.J., Humphreys M.H., Kopple J.D. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004, 80:299-307.
114. Carrero J.J., Qureshi A.R., Axelsson J., et al. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 2007, 85:695-701.
115. Sarraf P., Frederich R.C., Turner E.M., et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 1997, 185:171-175.
116. Daschner M., Tonshoff B., Blum W.F., et al. Inappropriate elevation of serum leptin levels in children with chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. J Am Soc Nephrol 1998, 9:1074-1079.
117. Mak R.H., Cheung W., Cone R.D., Marks D.L. Mechanisms of disease: cytokine and adipokine signaling in uremic cachexia. Nat Clin Pract Nephrol 2006, 2:527-534.
118. Stenvinkel P., Lindholm B., Lonnqvist F., Katzarski K., Heimburger O. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000, 11:1303-1309.
119. Mak R.H., Cheung W., Cone R.D., Marks D.L. Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney Int 2006, 69:794-797.
120. Cheung W., Yu P.X., Little B.M., Cone R.D., Marks D.L., Mak R.H. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005, 115:1659-1665.
121. de Vinuesa S.G., Goicoechea M., Kanter J., et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 2006, 17:S206-S212.
122. DeFronzo R.A., Alvestrand A., Smith D., Hendler R., Hendler E., Wahren J. Insulin resistance in uremia. J Clin Invest 1981, 67:563-568.
123. Tuzcu A., Bahceci M., Yilmaz M.E., Turgut C., Kara I.H. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease. Saudi Med J 2005, 26:786-791.
124. Shinohara K., Shoji T., Emoto M., et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002, 13:1894-1900.
125. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
126. Halse R., Pearson S.L., McCormack J.G., Yeaman S.J., Taylor R. Effects of tumor necrosis factor-alpha on insulin action in cultured human muscle cells. Diabetes 2001, 50:1102-1109.
127. Solomon S.S., Usdan L.S., Palazzolo M.R. Mechanisms involved in tumor necrosis factor-alpha induction of insulin resistance and its reversal by thiazolidinedione(s). Am J Med Sci 2001, 322:75-78.
128. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
129. Wakabayashi I. Age-related change in relationship between body-mass index, serum sialic acid, and atherogenic risk factors. J Atheroscler Thromb 1998, 5:60-65.
130. Marsland A.L., McCaffery J.M., Muldoon M.F., Manuck S.B. Systemic inflammation and the metabolic syndrome among middle-aged community volunteers. Metabolism 2010, 59:1801-1808.
131. Cordeiro A.C., Qureshi A.R., Stenvinkel P., et al. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant 2010, 25:562-568.